Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Feb;65(2):215–221. doi: 10.1038/bjc.1992.44

Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.

O Nilsson 1, C Johansson 1, B Glimelius 1, B Persson 1, B Nørgaard-Pedersen 1, A Andrén-Sandberg 1, L Lindholm 1
PMCID: PMC1977720  PMID: 1739620

Abstract

A serological assay for the quantitative determination of the novel tumour-associated epitope CA242 was developed and used for determination of sensitivity and specificity of CA242 in gastrointestinal cancer. The CA242 assay showed a better tumour specificity than CA50 (and CA 19-9). This was most noticeable in benign hepatobiliary disease. The sensitivity at 90% specificity cut-off level was approximately three times higher for CA242 compared to CA50 in colo-rectal cancer Dukes A, B and C, while in pancreatic cancer the sensitivity of CA242 and CA50 was similar. CA242 was expressed independently of CEA, and the combination of CEA and CA242 gave in colo-rectal cancer considerably higher sensitivity than the use of only one of the markers. This was most pronounced in Dukes A and Dukes B patients. CA242 is a novel tumour marker of potential clinical use, particularly in colo-rectal cancer.

Full text

PDF
215

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bonfrer J. M. Working Group on Tumor Marker Criteria (WGTMC) Tumour Biol. 1990;11(5):287–288. doi: 10.1159/000217662. [DOI] [PubMed] [Google Scholar]
  3. Cooper E. H., Knowles J. C., Parker D., Taylor M. An evaluation of serum CA 50 levels in cancer using a time-resolved fluoroimmunoassay. Biomed Pharmacother. 1988;42(3):189–196. [PubMed] [Google Scholar]
  4. DUKES C. E., BUSSEY H. J. The spread of rectal cancer and its effect on prognosis. Br J Cancer. 1958 Sep;12(3):309–320. doi: 10.1038/bjc.1958.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Del Villano B. C., Brennan S., Brock P., Bucher C., Liu V., McClure M., Rake B., Space S., Westrick B., Schoemaker H. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983 Mar;29(3):549–552. [PubMed] [Google Scholar]
  6. Haglund C., Kuusela P., Jalanko H., Roberts P. J. Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9. Int J Cancer. 1987 Apr 15;39(4):477–481. doi: 10.1002/ijc.2910390412. [DOI] [PubMed] [Google Scholar]
  7. Haglund C., Lindgren J., Roberts P. J., Kuusela P., Nordling S. Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br J Cancer. 1989 Dec;60(6):845–851. doi: 10.1038/bjc.1989.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Harmenberg U., Wahren B., Wiechel K. L. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract. Cancer Res. 1988 Apr 1;48(7):1985–1988. [PubMed] [Google Scholar]
  9. Hemmilä I., Dakubu S., Mukkala V. M., Siitari H., Lövgren T. Europium as a label in time-resolved immunofluorometric assays. Anal Biochem. 1984 Mar;137(2):335–343. doi: 10.1016/0003-2697(84)90095-2. [DOI] [PubMed] [Google Scholar]
  10. Hilkens J., Kroezen V., Bonfrer J. M., De Jong-Bakker M., Bruning P. F. MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res. 1986 May;46(5):2582–2587. [PubMed] [Google Scholar]
  11. Johansson C., Nilsson O., Baeckström D., Jansson E. L., Lindholm L. Novel epitopes on the CA50-carrying antigen: chemical and immunochemical studies. Tumour Biol. 1991;12(3):159–170. doi: 10.1159/000217701. [DOI] [PubMed] [Google Scholar]
  12. Johansson C., Nilsson O., Lindholm L. Comparison of serological expression of different epitopes on the CA50-carrying antigen CanAg. Int J Cancer. 1991 Jul 9;48(5):757–763. doi: 10.1002/ijc.2910480521. [DOI] [PubMed] [Google Scholar]
  13. Klug T. L., Bast R. C., Jr, Niloff J. M., Knapp R. C., Zurawski V. R., Jr Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. 1984 Mar;44(3):1048–1053. [PubMed] [Google Scholar]
  14. Kufe D., Inghirami G., Abe M., Hayes D., Justi-Wheeler H., Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma. 1984 Fall;3(3):223–232. doi: 10.1089/hyb.1984.3.223. [DOI] [PubMed] [Google Scholar]
  15. Lan M. S., Khorrami A., Kaufman B., Metzgar R. S. Molecular characterization of a mucin-type antigen associated with human pancreatic cancer. The DU-PAN-2 antigen. J Biol Chem. 1987 Sep 15;262(26):12863–12870. [PubMed] [Google Scholar]
  16. Lindholm L., Holmgren J., Svennerholm L., Fredman P., Nilsson O., Persson B., Myrvold H., Lagergård T. Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol. 1983;71(2):178–181. doi: 10.1159/000233384. [DOI] [PubMed] [Google Scholar]
  17. Magnani J. L., Steplewski Z., Koprowski H., Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983 Nov;43(11):5489–5492. [PubMed] [Google Scholar]
  18. Metz C. E. Basic principles of ROC analysis. Semin Nucl Med. 1978 Oct;8(4):283–298. doi: 10.1016/s0001-2998(78)80014-2. [DOI] [PubMed] [Google Scholar]
  19. Minton J. P., Hoehn J. L., Gerber D. M., Horsley J. S., Connolly D. P., Salwan F., Fletcher W. S., Cruz A. B., Jr, Gatchell F. G., Oviedo M. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer. 1985 Mar 15;55(6):1284–1290. doi: 10.1002/1097-0142(19850315)55:6<1284::aid-cncr2820550622>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  20. Minton J., Chevinsky A. H. CEA directed second-look surgery for colon and rectal cancer. Ann Chir Gynaecol. 1989;78(1):32–37. [PubMed] [Google Scholar]
  21. Nilsson O., Månsson J. E., Lindholm L., Holmgren J., Svennerholm L. Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody. FEBS Lett. 1985 Mar 25;182(2):398–402. doi: 10.1016/0014-5793(85)80341-0. [DOI] [PubMed] [Google Scholar]
  22. Ouyang Q., Vilien M., Juhl B. R., Larsen L. G., Binder V. CEA and carbohydrate antigens in normal and neoplastic colon mucosa. An immunohistochemical study. Acta Pathol Microbiol Immunol Scand A. 1987 Jul;95(4):177–183. doi: 10.1111/j.1699-0463.1987.tb00028_95a.x. [DOI] [PubMed] [Google Scholar]
  23. Stähli C., Takacs B., Miggiano V., Staehelin T., Carmann H. Monoclonal antibodies against antigens on breast cancer cells. Experientia. 1985 Nov 15;41(11):1377–1381. doi: 10.1007/BF01949996. [DOI] [PubMed] [Google Scholar]
  24. Sunderman F. W., Jr Current concepts of "normal values," "reference values," and "discrimination values," in clinical chemistry. Clin Chem. 1975 Dec;21(13):1873–1877. [PubMed] [Google Scholar]
  25. Touitou Y., Bogdan A. Tumor markers in non-malignant diseases. Eur J Cancer Clin Oncol. 1988 Jul;24(7):1083–1091. doi: 10.1016/0277-5379(88)90113-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES